Related by context. All words. (Click for frequent words.) 76 Project QTDP 72 Qualifying Therapeutic Discovery 71 Therapeutic Discovery Project 71 QTDP 70 Discovery Project QTDP 70 Project QTDP Program 69 Qualified Therapeutic Discovery 68 Government Qualifying Therapeutic 64 IRS Qualifying Therapeutic 64 Therapeutic Discovery 63 QTDP grant 62 QTDP program 61 Fast Track Status 61 Files IND 61 Orphan Drug designation 60 Awarded Qualifying Therapeutic 60 Orphan Drug designations 60 Integrated Preclinical 59 Submits Biologics License Application 59 Initiates Enrollment 59 Submits Response 59 SBIR Grant 59 acetonide FA 59 QTDP grants 59 Fast Track designations 59 Receive Milestone Payment 59 Initiate Clinical Trial 59 Zenvia ™ 59 COLAZAL R 58 personalized cellular immunotherapy 58 Initiates Phase II 58 vapreotide acetate 58 Friedreich Ataxia FRDA 58 Nascobal ® 58 Files Investigational 57 Translational Science Award 57 targeted radiotherapeutic 57 SBIR grant 57 NanoTab 57 SBIR Phase II 57 Commercialization Assistance Program 57 Potelligent Technology 57 Spiegelmer ® 57 MOVIPREP R 57 ALN PCS 57 CIP TRAMADOL ER 57 NASDAQ ENMD 57 Development Authority BARDA 57 OTCBB HXBM developer 57 Oracea TM 56 Aloxi Injection 56 HUD Continuum 56 NIH SBIR 56 BioSante Pharmaceuticals Announces 56 Phase #b/#a clinical 56 Receives Milestone Payment 56 Protexia ® 56 anti botulism antibody 56 Licenses Novel 56 Prodarsan R 56 liver resection surgeries 56 TKM Ebola 56 BEMA ® 56 aerosolized AAT 56 HHSN#C 56 NYSE Amex PTN 56 POSIDUR TM ELADUR TM 56 Biologic License Application BLA 56 By JAMAAL ABDUL 56 STTR grants 56 REGENERX BIOPHARMACEUTICALS INC. 56 PentaStaph 56 Protexia R 55 AVP #D# 55 NIH NIAID 55 XOMA 3AB 55 lexidronam injection 55 AAG geldanamycin analog 55 Gamunex C 55 Nasdaq PPHM 55 Nascobal R 55 RAPTIVA 55 Biological License Application 55 Captisol ® 55 Kosan dependence 55 Xcytrin R 55 anthrax monoclonal antibody 55 Bellicum 55 diagnostic molecular imaging 55 Program BIP 55 KNS # 55 topically applied SEPA 55 arsenic trioxide injection 55 Restanza TM 55 mGluR2 positive 55 novel histone deacetylase 55 NasdaqGM NTEC today 55 recombinant biopharmaceutical 55 Nabi HB Intravenous 55 STTR grant 55 nasal calcitonin product 55 LUCASSIN 55 NetLogic Microsystems Reports Inducement 55 Frova ® 55 Argatroban 55 Boehringer Ingelheim MedImmune 55 SansRosa 55 intranasal formulation 55 Orphan Drug Designation 54 EvaMist TM 54 Investigational Device Exemption 54 Avanir Pharma 54 Program MTEP 54 Nasdaq VRTX 54 RANK Ligand inhibitor 54 molecular imaging radiopharmaceutical 54 MAA submission 54 Fentanyl TAIFUN R 54 pralatrexate injection folate analogue 54 Nasdaq VNDA 54 Milestone Payment 54 ELADUR ™ 54 EHT AGN 54 zolpidem tartrate sublingual tablet 54 Anthim 54 Fast Track Designation 54 Panzem R 54 delivers fluocinolone acetonide FA 54 Orphan Drug Status 54 miconazole Lauriad R 54 non nucleoside inhibitor 54 TKB# 54 Miraculins Announces 54 Orphan Drug status 54 Milestone Payment From 54 FOLOTYN ® 54 NMTC Program 54 PDE4 inhibitor 54 dextromethorphan quinidine 54 Dannon Next Generation 54 Million Milestone Payment 54 submitted Biologics License 54 Prochymal TM 54 NCPA accepts 54 candidate REP# 54 BioMarck 54 PHASE III 54 vinorelbine emulsion 53 Application MAA 53 SparVax ™ 53 Milestone Payments 53 EpiTherapeutics 53 autologous cellular immunotherapy 53 Application BLA 53 PSIC Grant 53 Xcellerated T Cells 53 SYCREST 53 Earns Milestone Payment 53 INSPIRE Trial Phase III 53 Sanvar R 53 ABL inhibitor 53 MAGE A3 ASCI 53 Task Orders 53 CCR5 mAb 53 immunotherapeutic vaccine 53 ZALBIN ™ 53 Closes Oversubscribed 53 Aryplase 53 Proellex TM 53 Intravenous Human 53 orphan designation 53 ABthrax TM 53 traunch 53 CINTREDEKIN BESUDOTOX 53 Bioral Amphotericin B 53 diagnostic radiopharmaceutical 53 acyclovir Lauriad R 53 Meritage Pharma 53 JAK2 Inhibitor 53 IND Investigational New 53 DiaPep# 53 Protease Inhibitor 53 EVIZON TM 53 Zegerid OTC 53 PHX# 53 prokinetic agent 53 P#X# antagonist 53 SBIR Phase 53 XL# anticancer compounds 53 please visit http:/www.atherogenics.com 53 PLK1 SNALP 53 dacetuzumab collaboration 53 Zorbtive TM 53 Xoma Ltd 53 topical anti infective 53 Phase IIb Trial 53 SinuNase ™ 53 Vantex Completes 53 registrational studies 53 Humanitarian Device Exemption 53 Evoltra ® 53 CEL SCI Phase III 53 Sumatriptan Succinate 53 Intermediary Relending Program 53 Simulect 53 DELAP 53 Cellegesic 53 BioThrax R 53 GeoVax AIDS vaccine 53 TSX VENTURE URO 53 Civacir 53 DP VPA 53 Opterone R 53 Phase IIb Clinical Trial 53 markets Gelclair R 53 CD# CEA 52 candidate XP# 52 Zenvia TM 52 PROGENSA R 52 AnGes MG Inc. 52 lintuzumab SGN 52 Ambulatory EHR ensures 52 Pivotal Phase III 52 GlaxoSmithKline Tykerb 52 Glybera R 52 NEUMUNE 52 MathMovesU scholarship 52 AI# [001] 52 Inc. NASDAQ ZLCS 52 Sensipar R 52 LymphoStat B belimumab 52 Iluvien ® 52 submit Biologics License 52 % uracil topical 52 Octreolin 52 TKM PLK1 52 ALN TTR 52 CIMZIA r 52 TRX1 52 PNP inhibitor 52 Arzerra ofatumumab 52 ASONEP TM 52 release intravitreal insert 52 NASDAQ OSIR 52 GRANT FOR 52 CFFT 52 oral prodrug 52 USD3m 52 mesylate tablets approved 52 OTC ZEGERID 52 dutogliptin 52 LymphoStat B TM 52 PF # [002] 52 PREOS R 52 InterfeRx 52 BioDelivery Sciences 52 THALOMID 52 StaphVAX R 52 BUPHENYL R 52 GTC recombinant form 52 Initiate Phase 52 Program VICP 52 Agri Opportunities 52 IMiDs 52 ENTEREG ® 52 Abdullah Batarfi Yasir 52 candidate NGX 52 Curacyte 52 hoFH 52 Glybera 52 Hsp# Inhibitor 52 oral nucleoside analogue 52 Tiuxetan 52 Primera Bioscience 52 adecatumumab MT# 52 Wellcome Trust Seeding 52 Testosterone MDTS ® 52 candidate Zenvia 52 Lenocta TM 52 CIP ISOTRETINOIN 52 Gadavist 52 Methylphenidate Transdermal System 52 Finance Authority KEDFA 52 Anturol TM 52 ALN HTT 52 oral deforolimus 52 Solazed TM 52 memantine HCl 52 Nasdaq ALNY 52 Crazy Heart Mo'Nique 52 Premarket Approval 52 Voraxaze 52 OROS R Hydromorphone 52 R bendamustine hydrochloride 52 NASDAQ ARRY 52 Vaccinex 52 BFTDA 52 Cetirizine Hydrochloride Syrup 52 Merck OSI Pharmaceuticals 52 outlicensed 52 lucinactant 52 Drug Submission 52 dasatinib Sprycel ® 52 granted Ortec 52 Transformational Medical 52 ROTATEQ 52 exclusive sublicense 52 Neovasc Reducer 52 Financial Institutions CDFI Fund 52 MEK Inhibitor 52 NMTCs 52 IAP inhibitor 52 severe hypercholesterolemia 52 RxKinetix 52 Orapred ODT 52 investigational hepatitis B 52 Somatuline Depot 52 refractory chronic lymphocytic 51 EVIZON ™ 51 Repowering Assistance Program 51 Translational Science Awards 51 ZEVALIN ® 51 Exclusive License 51 GTC recombinant human 51 Synerx 51 Allovectin 7 51 NMTC allocation 51 NSP2 51 leading oral taxane 51 rolling Biologics License 51 NYS CDBG 51 Fillanthropy Program 51 PANVAC VF 51 Factor VIIa 51 molecular chaperone regulation 51 subcutaneous formulation 51 dacetuzumab SGN 51 BILLION FOR 51 HCV NS5B polymerase 51 reslizumab 51 overactive bladder AA# 51 Phenomix Corporation 51 directed radiotherapeutic antibody 51 mitogen activated ERK kinase 51 HepeX B TM 51 WIRED grant 51 Solzira TM 51 investigational oral hepatitis C 51 NIH NHLBI 51 SURFAXIN 51 Expression Genetics 51 Opportunity Announcement FOA 51 Therapeutic Discovery Tax 51 Merz Pharmaceuticals GmbH 51 NFMC Program 51 Sigma Tau Pharmaceuticals 51 topical ophthalmic 51 programs visit http:/www.nih.gov/ 51 Prodarsan ® 51 Paris IPN Euronext 51 sodium Injection 51 Matching Grants 51 ISSUED TO 51 Contingent Value Right 51 CEFF financings subject 51 Albugon 51 Lenocta 51 NHGRI Division 51 TRISENOX ® 51 raxibacumab 51 Oncaspar 51 Loan Repayment Program 51 ENTB 51 developing Zerenex ferric 51 sNDAs 51 Somatuline R Autogel R 51 mertansine 51 product platforms AZX# 51 Assistance Program NRC IRAP 51 Enkephalin 51 Sopherion Therapeutics 51 Personalized Immunotherapy 51 highly purified pasteurized 51 Phase IIa Clinical Trial 51 MBMI Closes 51 Cloretazine ® 51 methylnaltrexone bromide 51 histone deacetylase HDAC inhibitor 51 Amigal TM 51 Symphony Dynamo 51 HepeX B 51 Thrombin topical Recombinant 51 Section #D 51 Units RSUs 51 Neurogen stockholders 51 Marketing Authorisation Application MAA 51 hypoxia activated prodrug 51 ARRY # 51 II SBIR 51 REVENUE BONDS SERIES 51 Raptiva R 51 Premarket Approval PMA 51 SenterNovem 51 intradermal injections 51 Actemra tocilizumab 51 MCSP respectively 51 PI3K/Akt pathway inhibitor 51 NSF SBIR 51 SinuNase TM 51 Wellstat 51 Acetavance TM 51 AzaSite Plus 51 phase IIb study 51 Foundation ADDF 51 BioThrax ® 51 trastuzumab DM1 T DM1 51 G#DT 51 Nasdaq VICL 51 HDAC Inhibitor 51 Inc. NASDAQ XNPT 51 markets Testim ® 51 Cooperative Agreements 51 Zalypsis 51 Q#IR 51 Fibrillex TM 51 NASDAQ PGNX 51 Ketotransdel 51 apoptosis inducer 51 ADVEXIN p# therapy 51 Nasdaq OPTR 51 histamine dihydrochloride 51 QTDP Program 51 non nucleoside HCV 51 Biologics License Application BLA 51 Serostim ® 51 FUNDED BY 51 Xyfid TM 51 samarium Sm 51 EVIZON TM squalamine lactate 51 Maribavir 51 Technology Transfer STTR 51 rusalatide acetate 51 CINQUIL 51 novel VDA molecule 51 Vivelle Dot ® 51 Program WRP 51 MERREM IV 51 H2O PA 51 supplemental Biologics License Application 51 STEDESA 51 DOR# 51 Lexiscan TM 51 Phase lll 51 selective androgen receptor modulator 51 MT#/MEDI-# 51 Nanobody R 51 TAXS.OB 51 Phase IIa trials 50 Oncolys 50 certolizumab 50 Academic Enrichment Grants 50 Mepact 50 SAR# [002] 50 antibody MAb 50 Composite Coatings 50 NASDAQ ALNY 50 drug ISA# 50 investigational atypical antipsychotic 50 Non Dilutive 50 Inc. OTCBB MBCI 50 Grants Totaling 50 Exelixis logo 50 Phase 2a clinical trials 50 Phase Ib clinical trials 50 NTIA Broadband 50 motexafin gadolinium Injection 50 Ganite ® 50 ARRA HITECH 50 sapropterin dihydrochloride 50 Daytrana TM 50 subgrant 50 Title XVII 50 Rotarix R 50 selective A2A adenosine receptor 50 allosteric modulator PAM 50 FDA Approvable Letter 50 refractory APL 50 Financial Institution CDFI 50 Onco TCS 50 diarrhea predominant irritable 50 Genasense ® oblimersen 50 rALLy clinical trial 50 antiinfective 50 Soliris TM eculizumab 50 rufinamide 50 Receives ONC ATCB 50 Prednisporin 50 Zemplar Capsules 50 miRNA therapeutics 50 ILUVIEN ® 50 RR# [001] 50 NASDAQ GNTA 50 Optiquel ™ 50 OMAPRO ™ 50 exocrine pancreatic insufficiency EPI 50 TolerRx 50 OTCQX QRXPY 50 BEIP grant 50 NASDAQ PSDV ASX 50 RTP #i 50 GLP1 INT TM 50 initiated Phase Ib 50 omacetaxine mepesuccinate 50 FACTIVE R gemifloxacin 50 AnorMED expectation 50 Potent Compound Safety 50 Commercialising Emerging Technologies 50 RAPTIVA r 50 Loan Guarantee Program 50 TRACON Pharmaceuticals 50 recombinant interferon 50 include Phenoptin TM 50 NASDAQ REGN 50 GLP toxicology 50 HCV polymerase 50 XP# XP# 50 application sNDA 50 Grant Program HSGP 50 Urocidin TM 50 Idenix Novartis 50 relapsing multiple sclerosis 50 MAXY alpha 50 pegylated alpha interferon 50 Zelrix 50 Sinuwave 50 PNT# 50 compound ISA# 50 lead Aganocide compound 50 Estuarine Land 50 RenaZorb TM 50 NMTC allocations 50 CCHIT Certification 50 topical non steroidal 50 Submits Investigational 50 AGTC 50 Augment TM 50 AMEX ONI 50 Incentive Grants 50 commercialized DURECT 50 Anavex #-# 50 Emezine 50 Marketing Authorization Application 50 erlotinib Tarceva ® 50 ATryn ® 50 Anturol ® 50 PrimeSUITE ® 50 virus HCV protease inhibitor 50 Mentor Protege Program 50 ALN TTR# 50 Campto 50 Arikace 50 NSF Integrative Graduate 50 Rocmec Closes 50 TKM ApoB 50 forodesine 50 Taiho Pharmaceutical 50 diabetes irritable bowel 50 Diabetic Macular Edema DME 50 Syntonix 50 Solzira 50 XIAPEX 50 Augment ™ 50 CCR9 antagonist 50 Committed Equity 50 cyclobenzaprine hydrochloride extended 50 Assistance DUA 50 fusion enhancers 50 WHO 'S SWITCHING 50 HCV protease inhibitor 50 Onalta ™ 50 sarcoma melanoma 50 Closes Private Placements 50 Autologous Thrombin Processing 50 EvaMist 50 Million Convertible Debt 50 Contracts Totaling 50 JOULFERON 50 iv peramivir 50 Phase IIb clinical trials 50 Fast Track designation 50 Nerve Targeting Drug 50 Anidulafungin 50 IMVAMUNE ® 50 Trastuzumab DM1 50 Psivida 50 Naglazyme R 50 POTELLIGENT R Technology 50 liposomal formulation 50 MorphoSys proprietary 50 L BLP# 50 RBEG 50 investigational pan BCR 50 Assistance Program SCAAP 50 CalHome 50 anti CD3 monoclonal 50 Ceflatonin R 50 CIP Fenofibrate 50 Incumbent Worker 50 Program CERP 50 oral methylnaltrexone 50 Begin Clinical Trials 50 SIPconnect Compliant Certification 49 OMNARIS HFA 49 Nasdaq MBRX 49 candidates bavituximab 49 Elagolix 49 STTR Phase 49 Diabetic Macular Edema 49 Job Creation Tax Credits 49 Million Subcontract 49 huC# DM4 49 Senior Unsecured Term 49 Investigational Device Exemption IDE 49 MyVax R 49 Staphylococcus aureus Polysaccharide Conjugate 49 Private Equity Financing 49 Subpart E 49 Entereg R 49 LibiGel ® 49 TRANSDUR TM Sufentanil 49 immunosuppressive compound 49 ONC ATCB Complete EHR 49 Obtains License 49 Inhibiton 49 investigational humanized monoclonal antibody 49 Research Initiative AFRI 49 Customized Job 49 BLA submission 49 Seeding Drug 49 Economic Opportunity DCEO 49 VANTAS ® 49 HHS Substance Abuse 49 OrCel ® 49 Student Loan Repayment 49 Alvesco R 49 Authority PIDA 49 BioGeneriX 49 Biologic License Application 49 FDA Investigational Device 49 Issues Guidance 49 Frova R 49 FNIH 49 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 49 LEVADEX TM 49 Galderma SA 49 Archexin 49 GSHN 49 Obama Refi Programs 49 eligen R technology 49 anticancer compound 49 Proquin XR 49 Astex Therapeutics Limited 49 Exalgo TM 49 HUD Neighborhood Stabilization 49 via intradermal injections 49 Emergency Response SAFER 49 incyclinide 49 containing granisetron 49 Sumavel DosePro 49 eprodisate KIACTA TM 49 Clean Water SRF 49 mesylate tablets 49 GATTEX ® 49 Inc POZN 49 PDX pralatrexate 49 Firefighters Grants AFG 49 TELINTRA 49 Study Validates 49 RNAi therapeutic targeting 49 Allovectin 7 r 49 Daraa martyrs 49 Nasdaq DVAX 49 Nasdaq HALO 49 Patient Assistance Program 49 PSMA ADC 49 lymphoid malignancies 49 Fanapt ® 49 Minority Serving Institutions 49 biofuels bioenergy 49 Alnara Pharmaceuticals 49 Preotact 49 Ethyol 49 Postdoctoral Fellowship 49 SNT MC# 49 PD2i ® algorithm 49 Cutanea Life Sciences 49 SGIG 49 Combidex 49 IMVAMUNE R 49 ZALBIN 49 Inc. AMEX YMI 49 AeroLEF 49 Daclizumab 49 Stedesa 49 Soliris eculizumab 49 Dacetuzumab 49 oral ridaforolimus 49 proprietary albumin fusion 49 Troxatyl 49 Ostarine TM 49 Job Creation Partnerships 49 Hiberix 49 Tarceva TM 49 Kuvan TM sapropterin 49 ORADUR ADHD 49 National Foreclosure Mitigation 49 PROVENGE ® 49 Mentor Protege Agreement 49 oxymorphone ER 49 ThermoDox R 49 FRDA 49 compound PMX # 49 opioid induced bowel dysfunction 49 IGXT IntelGenx today 49 ALN RSV program 49 DIAGNOS Announces 49 Dupuytren Contracture 49 accumulate preferentially 49 registrational 49 topically administered 49 Barr ANDA 49 Australian Therapeutic Goods 49 NASDAQ ENZN 49 cutaneous T 49 Golden LEAF Rural 49 cinacalcet HCl 49 Upfront Payment 49 R pegaptanib sodium 49 oral opioid modulator 49 IMA# 49 Development HCD 49 Perforomist TM formoterol fumarate 49 Generx ™ 49 SAFER grants 49 developing adecatumumab 49 AeroLEF TM 49 Program EQIP 49 k premarket 49 Loramyc TM 49 Fortical ® 49 winning DEMOletter 49 Avian Transgenic Technology 49 Dextofisopam 49 ANIK 49 NASDAQ EPMD 49 chiropractic acupuncture massage 49 Cyclooxygenase Inhibiting Nitric Oxide 49 Agriculture USDA Rural 49 ISENTRESS raltegravir 49 Funding Commitment 49 DOE Smart Grid 49 Assis tance 49 NASDAQ DYAX 49 SomatoKine 49 Eligard R 49 Vion Pharmaceuticals 49 BioMarin Genzyme LLC 49 ResponseDX 49 Qutenza TM 49 Allovectin 7 R 49 Unit Dose Budesonide 49 PROPOSES TO 49 Marketing Authorisation Application 49 ARIKACE ™ 49 Project BioShield Act 49 Gastrotech 49 GALNS 49 Nasdaq ABII 49 opioid induced constipation OIC 49 S OMX GEN 49 pseudobulbar affect PBA 49 huN# DM1 49 Ceflatonin ® 49 Orders Totaling Approximately 49 Reintegration Program 49 Zavesca ® 49 glucokinase activator 48 CDFI Program 48 Onalta 48 GTHP 48 gastrointestinal disorders characterized 48 elotuzumab 48 ONC ATCB certified 48 Lexiscan ® 48 NASDAQ IDEV 48 Tectin TM 48 AMA PRA 48 Alinia 48 Inc. Nasdaq IDMI 48 antibiotic candidate Ramoplanin 48 IV APAP 48 Emtriva emtricitabine 48 TREAT ALS 48 multicenter Phase III 48 AQ4N 48 ruxolitinib 48 JZP 48 balsalazide tablet 48 Seroquel quetiapine fumarate 48 CRMD# 48 Aerosurf 48 Icatibant 48 OTCBB PYTO 48 volociximab 48 Pertuzumab 48 Veterans Affairs Supportive Housing 48 CEDAP 48 COPS Hiring Program 48 lenalidomide Revlimid R 48 OLpur TM H2H 48 Marketing Authorization Application MAA 48 JUVISTA 48 Chaim Lebovits President 48 Pruvel 48 phase Ib clinical 48 Opportunities Program BTOP 48 CBLB# 48 ESTRASORB ® 48 Apprenticeship Incentive Grant 48 Lamictal ODT 48 Abstral 48 Quinvaxem R 48 nalbuphine ER 48 Neighborhood Assistance Program 48 catheter occlusion 48 CSREES 48 LGLS 48 Integrative Graduate Education 48 Program ERRP 48 Orphan Drug 48 CCHIT Ambulatory EHR 48 Ophthotech 48 Cheneys owed 48 orally administered inhibitor 48 Convertible Promissory Note 48 curing muscular dystrophy 48 PRNewswire FirstCall Genta Incorporated 48 Kyowa Kirin 48 Non Brokered Financing 48 selective immunoproteasome inhibitor 48 Ophena TM 48 Pliaglis 48 SRA Awarded 48 Rhucin ® recombinant 48 Luna Innovations Announces 48 Research Traineeship 48 TD Banknorth Charitable Foundation 48 Phase III Pivotal 48 TOLMAR Holding Inc. 48 Nasdaq MBRX announced 48 subgrants 48 Junovan TM 48 Executive Order #g 48 ALS Charitable Remainder 48 ABRAXANE ® 48 Program TLGP 48 trading symbol GCKO 48 VitiGam 48 RhuDex ® 48 Aztreonam lysine 48 oxybutynin ATD TM 48 IND submission 48 Fx #A 48 RIGScan ™ 48 Phase IIIb clinical 48 thrombin component 48 rheumatoid arthritis psoriatic arthritis 48 Exherin TM 48 Celgene Thalomid 48 Alternative Fuels Incentive 48 Resten NG 48 Protectan CBLB# 48 BLA filing 48 Program HMGP 48 TSX VENTURE MBI 48 MedGenesis 48 Broadband Initiatives 48 LITC 48 protein hydrogel 48 Adequate Fire 48 sargramostim 48 QNEXA ® 48 CITY MOVES 48 NeuroSolutions 48 Phase IIB 48 Fostering Effective Technologies 48 Mediphase Venture Partners 48 AARA 48 Pharmos pipeline 48 tezampanel NGX# 48 ASG 5ME 48 Premarket Notification 48 investigational antiplatelet agent 48 Nasdaq MITI 48 supplemental biologics 48 Closes Flow Through 48 Phase 1a clinical 48 GSA Contract 48 Graniz Loan 48 injectable influenza 48 Esbriet pirfenidone 48 oxaliplatin injection 48 Innodia Inc. 48 repayable contribution 48 STRIANT 48 generation purine nucleoside 48 INDs 48 Agriculture NIFA 48 PrevOnco 48 Tax Incentive Program 48 TARP CPP 48 Initiative ADDI 48 Fund CCEF 48 Million Non Brokered 48 Investigator Initiated 48 dermatological indications 48 ALVESCO R 48 dependent kinase inhibitor 48 TSX PLB leading 48 HITECH provisions 48 SPRIX ® 48 Stavzor 48 NIH NCRR 48 Rent Rebate Program 48 NASDAQ BPAX 48 Onrigin 48 Shire BioChem Inc. 48 Inc. Nasdaq VVUS 48 Postdoctoral Fellowships 48 Linjeta TM 48 granulated mesalamine 48 MoxDuo TM IR 48 ACTIQ 48 rosiglitazone maleate 48 Burroughs Wellcome Fund 48 Fancamp Announces 48 SparVax 48 DE FOA # 48 Zor Pharmaceuticals 48 RenaMed 48 generation URAT1 inhibitor 48 promotes MERREM ® 48 ZEGERID Capsules 48 FORADIL 48 sorafenib tablets 48 refractory Hodgkin lymphoma 48 Locteron ® 48 Announces Granting 48 Aileron Therapeutics 48 mGluR5 negative 48 AnGes 48 BEMA Buprenorphine 48 Inc MEDX 48 Phase IIb trials 48 AusIndustry 48 Sular ® 48 ImmunoGen TAP technology 48 SBIR grants 48 oral proteasome inhibitor 48 PDL BioPharma Announces 48 Grant Program AFGP 48 ViroChem 48 phase IIb clinical 48 SHIPs 48 LUCENTIS r 48 Drinking Water SRF 48 related CMV Retinitis 48 develop bioterrorism countermeasures 48 GLP toxicology studies 48 Metabasis stockholders 48 Cellpep 48 Cethrin 48 polyneuropathy HIV DSP 48 defensin mimetic antimicrobial 48 Blight Elimination 48 Lumacan 48 ATL# [002] 48 injectable formulation 48 Zelapar 48 RX ACCULINK 48 Entereg TM 48 CDFI Fund 48 Loramyc ™ 48 confirmatory Phase III 48 research anddevelopment 48 multicenter Phase II 48 sterile lidocaine patch 48 IMiDs R 48 PRNewswire FirstCall OncoGenex Pharmaceuticals